MOUD Buprenorphine Subli denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for moud buprenorphine subli are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Would Deny Sublingual Buprenorphine as "Experimental"

This denial type applied to sublingual buprenorphine for opioid use disorder is, in most circumstances, clinically and legally indefensible — and therefore highly appealable. Buprenorphine has been FDA-approved for the treatment of opioid dependence/opioid use disorder for more than two decades. It is endorsed as a first-line treatment by every major addiction medicine body and by federal agencies including SAMHSA and the FDA. An "experimental or investigational" denial for an on-label, long-approved MOUD medication almost certainly reflects an administrative coding error, an incorrect claims submission, or an insurer applying an outdated or inapplicable policy.

## Why This Denial Is Appealable

Aetna's definition of "experimental" or "investigational" requires that a treatment lack sufficient clinical evidence of safety and effectiveness. Sublingual buprenorphine clearly does not meet that definition when used for OUD. In addition, the federal Mental Health Parity and Addiction Equity Act (MHPAEA) prohibits applying utilization-management restrictions — including experimental denials — to substance use disorder treatment that are more burdensome than restrictions applied to analogous medical or surgical benefits. A well-documented appeal citing the FDA approval, established clinical guidelines, and the MHPAEA parity obligation is very strong.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File within the deadline on your denial letter. Request the specific policy language and clinical criteria Aetna applied.
• MHPAEA parity claim: Explicitly raise the parity issue in your appeal letter. Ask Aetna to identify the comparable medical/surgical benefit and demonstrate that its experimental criteria are applied equivalently.
• External review (ACA §2719): An independent external organization — not Aetna — reviews the case and issues a binding determination. The window is approximately 4 months from the final internal denial.
• Expedited review: Available for urgent situations; turnaround is 72 hours. Interruption of buprenorphine therapy can pose serious health risks, which may qualify as urgent.
• State insurance commissioner: If the denial persists, a complaint to your state's insurance regulator is appropriate for what may be a bad-faith denial of a long-approved medication.

## Documentation to Gather

1. FDA approval documentation — the current FDA-approved prescribing information for sublingual buprenorphine, available at DailyMed. 2. Diagnosis confirmation — clinical records confirming an opioid use disorder diagnosis and the treating clinician's assessment. 3. SAMHSA/clinical guideline reference — your prescriber should reference applicable federal and professional society MOUD guidelines by organization name. 4. Prescriber letter — directly rebutting the experimental finding and citing the FDA approval date and indication. 5. MHPAEA comparison request — in your appeal, formally ask Aetna to provide the comparable medical/surgical benefit and its utilization-management criteria.

## Criteria-Mapping Structure

Request the exact policy Aetna used to classify this treatment as experimental. Compare each criterion in that policy to the FDA label, established guidelines, and clinical literature. Present the comparison in your appeal letter. The goal is to demonstrate that no reasonable interpretation of "experimental" applies to a treatment with this regulatory and clinical history.